Development of novel pain relief agents acting through the selective activation of the delta-opioid receptor.
A continuing effort in the development of non-peptide delta-opioid agonists as possible safe and effective pain relief agents has been seen in the last years. Novel potent and selective delta-opioid agonists based on the pirrolomorphinan framework have been designed, synthesised and biologically characterised in our laboratories. In particular, compound 7 (SB 235863) proved the concept that a selective delta-opioid agonist may be a valuable pain relief agent free of the unwanted side-effects usually associated with narcotic analgesics such as morphine.
SmithKline Beecham S.p.A., Department of Medicinal Chemistry, Milan, Italy. massimo_dondio@sbpharm.com
G
G
Dondio
D000701:Analgesics, Opioid / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000378:metabolism; D002460:Cell Line; D008958:Models, Molecular; D051381:Rats; D017465:Receptors, Opioid, delta / Q000187:drug effects*; D013329:Structure-Activity Relationship
D000701:Analgesics, Opioid; D017465:Receptors, Opioid, delta